# e-Learning for Healthcare (e-LfH) for STIF Competency Pathways



THE STI FOUNDATION

NHS England

elfh
elearning for healthcare

Sexual Health & HIV (HIV-STI)

Sexual and Reproductive Health (e-SRH)

Advanced Therapy Medicinal Products (ATMP)

Domestic Violence and Abuse (DVA)

Safeguarding Children and Young People (SGC)

Dermatology (e-Derm)

Immunisation (IMM)

NHS Learning Hub

# e-Learning for Healthcare (e-LfH) for STIF Competency Pathways

**You will be asked to provide proof of completion of the e-learning sessions and linking them directly to your e-portfolio from eLfH is designed to make this easy. https://www.youtube.com/watch?v=j5cCHLDCXj4 is available to help you do this.**

## NHS staff

If you are employed by the NHS in the UK and have an NHS email address you can register for free access to eHIV-STI via the e-LfH Hub by completing the registration form on the e- LfH website:  http://portal.e-lfh.org.uk/Register Please note that NHS email addresses include @nhs.net, @*trustname.nhs.uk and the equivalent in Scotland, N Ireland and Wales.* Once NHS users have registered for e-learning, there is no expiry time on the account.

Any e-learning which is not hosted on HEE eLfH needs to be documented and verified. Please ensure that you print a suitable certificate of proof of having undertaken the e-learning and upload this to your 'personal library'

## Non-NHS staff (including those working outside the UK)
**This group of users will need to pay for access to eHIV-STI.**
Go to https://www.eintegrity.org/  for more information

> *Please note that eHIV-STI is not administered by BASHH and we cannot assist with registration/access problems - if you still have problems after using the above information and resources please contact e-LfH via their Support Form: http://portal.e- lfh.org.uk/support/*

**It is required that you revise the eLfH sessions done as part of the STIF Competency training if more than 3 years have elapsed since you completed them. E-learning sessions dated more than 3 years before your registration will not be counted as complete**

1. **Register for Sexual Health and HIV**



2. **Choose HIV-STI: STIF Pathways**

**3.  Choose the pathway you are following:**

- STIF Course
- STIF Fundamental
- STIF Gateway
- STIF Intermediate
- STIF Integrated
- STIF Advanced
- STIF SHA
- STIF NHIVNA Intermediate
- STIF NHIVNA ADVANCED

**The e-learning sessions required for each pathway are listed below.**

# STIF Fundamental Competency

| Sexual Health & HIV (HIV-STI) | |
|---|---|
| 00_01 | Fundamentals of Sexual History |
| 01_01 | Sexual Behaviour and Infection Risk |
| 01_03 | Confidentiality in Sexual Health |
| 01_07 | Chaperones and Consent |
| 01_12 | Screening Asymptomatic Patients |
| 01_14 | Partner Notification When and How |
| 03_05 | Chlamydia Trachomatis: Natural History and Management |
| 11_01 | HIV Testing |

# STIF Gateway Competency

| Sexual Health & HIV (HIV-STI) | |
|---|---|
| 00_01 | Fundamentals of Sexual History |
| 01_01 | Sexual Behaviour and Infection Risk |
| 01_03 | Confidentiality in Sexual Health |
| 01_07 | Chaperones and Consent |
| 01_12 | Screening Asymptomatic Patients |
| 01_14 | Partner Notification When and How |
| 03_05 | Chlamydia Trachomatis: Natural History and Management |
| 08_06 | Safeguarding in Practice |
| 11_01 | HIV Testing |
| | |
| **Immunisation (IMM)** | |
| 01_007 | Vaccine Administration<br>https://portal.e-lfh.org.uk/LearningContent/Launch/513914 |
| 02_007 | Vaccine Administration Assessment<br>https://portal.e-lfh.org.uk/LearningContent/Launch/513917 |
| 03_003 | Vaccine Preventable Diseases - Hepatitis B<br>https://portal.e-lfh.org.uk/LearningContent/Launch/482659 |
| 03_004 | Vaccine Preventable Diseases - Human Papillomavirus (HPV)<br>https://portal.e-lfh.org.uk/LearningContent/Launch/513851 |
| **Advanced Therapy Medicinal Products (ATMP)** | |
| | Safe use of low temperature transport vessels e-learning<br>https://portal.e-lfh.org.uk/LearningContent/Launch/648705 |
| | |

# STIF Intermediate Competency

| eLfH sessions | |
|---|---|
| **Sexual Health & HIV (HIV-STI)** | |
| **1.01** | Sexual Behaviour and Infection Risk |
| **1.02** | Sexual History |
| **1.03** | Confidentiality in Sexual Health |
| **1.04** | Male Anatomy and Physiology |
| **1.05** | Female Anatomy and Physiology |
| **1.07** | Chaperones and Consent |
| **1.08** | Male Genital Examination |
| **1.09** | Female Genital Examination |
| **1.10** | Examination of Extra-genital Sites |
| **1.11** | Clinical Signs in Genitourinary Medicine |
| **1.12** | Screening Asymptomatic Patients |
| 1.13 | Chlamydia Screening |
| 1.14 | Partner Notification, When and How? |
| 1.19 | Chemsex |
| 1.20 | Sexual / Reproductive Healthcare for Trans, Non-binary and Intersex People |
| | |
| 2.01 | Interpreting Laboratory Tests |
| **2.02** | Antigen and Antibody Tests |
| **2.03** | Nucleic Acid Amplification Tests |
| **2.04** | Diagnosing Gonorrhoea |
| **2.05** | Diagnosing Chlamydia |
| **2.07** | Diagnosing Trichomoniasis |
| **2.10** | Diagnosing Candidiasis |
| **2.11** | Diagnosing Bacterial Vaginosis |
| **2.12** | Diagnosing Genital Herpes |
| **2.15** | Diagnosing HIV |
| | |
| **3.01** | Male urethritis: diagnosis and management |
| **3.03** | Gonorrhoea: natural history and management |
| **3.05** | Chlamydia trachomatis: natural history and management |
| **3.17** | Urinary Tract Infections |
| | |
| **4.01** | Genital Ulceration - Causes and Investigation |
| **4.06** | Genital Herpes Infections, Natural History and Complications |
| **4.07** | Genital Herpes, Virology and Pathogenesis |
| **4.09** | Initial and Recurrent Episode HSV |
| | |
| **5.01** | Genital Lumps |
| **5.02** | Differential Diagnosis of Ano-Genital warts |
| **5.03** | Ano-Genital Warts |
| | |
| **6.01** | Scabies and Pediculosis pubis (pubic lice) |
| | |
| **7.02** | Hepatitis A: Natural history and management |
| **7.03** | Hepatitis B: Natural history, presentation and investigation |
| **7.04** | Hepatitis C: Natural history, presentation and investigation |
| | |
| **8.01** | Consent, Competence & confidentiality for under18s |
| **8.02** | Indicators of child sexual abuse and exploitation |
| **8.03** | Sexual assault and exploitation in adults |
| **8.05** | Child sexual abuse (CSA) |

| | |
|---|---|
| | |
| **10.01** | Vaginal discharge |
| **10.02** | Trichomonas Vaginalis |
| **10.03** | Candida and yeast infections |
| **10.04** | Bacterial vaginosis |
| | |
| **11.01** | HIV Testing |
| **11.03** | HIV Disclosure and Partner Notification |
| **11.04** | Occupational Exposure to HIV |
| **11.05** | Sexual Exposure to HIV |
| **11.06** | Post Exposure Prophylaxis after sexual exposure (PEPSE) |
| | |
| **e-SRH** | http://www.e-lfh.org.uk/programmes/sexual-and-reproductive-healthcare/ |
| **01.05** | Working with Young People |
| | |
| **Safeguarding Children (SGC)** | http://www.e-lfh.org.uk/programmes/safeguarding-children |
| | Safeguarding Children - Level 1 |
| | Safeguarding Children - Level 2 |
| | Level 3 - Introduction: Attaining and Maintaining Safeguarding Competences |
| | |
| **Female Genital Mutilation (FGM)** | https://portal.e-lfh.org.uk/Component/Details/390922 |
| 01_02 | Communication skills for FGM Consultations |
| | |
| **Child Sexual Exploitation (CSE)** | https://www.e-lfh.org.uk/programmes/child-sexual-exploitation/ |
| | Combatting CSE |
| | |
| **Domestic Violence and Abuse (DVA)** | https://portal.e-lfh.org.uk/Component/Details/391662 |
| Mod 1 | Understanding domestic violence and abuse |
| Mod 2 | Identification of domestic violence and abuse |
| Mod 3 | Risk assessment for victims of domestic violence and abuse |
| | |

# STIF Integrated Competency

| | |
|---|---|
| **e-SRH 01 Basic Anatomy and Physiology** | |
| 01_01 | Basic Anatomy and Physiology |
| **e-SRH 02 Consent and History Taking** | |
| 02_01 | Health history and risk assessment |
| **e-SRH 03 Contraceptive Choices** | |
| 03_01 | Mechanisms of action, effectiveness and UKMEC |
| 03_02 | Choosing Contraceptive Methods |
| 03_03 | Combined Hormonal Contraception (CHC) Methods |
| 03_04 | Progestogen-only (PO) Methods (Oral and Injectable) |
| 03_05 | Subdermal Implant (SDI) |
| 03_06 | Intrauterine Contraception (IUC) |
| 03_07 | Barrier Contraceptives |
| 03_08 | Sterilisation |
| 03_09 | Fertility Awareness Methods and Apps |
| **e-SRH 04 - Emergency Contraception** | |
| 04_01 | Emergency Contraception |
| **e-SRH 05 - Contraception: Managing Side-effects and Complications** | |
| 05_01 | Managing Bleeding Problems in Women using Contraceptives |
| 05_02 | Managing Contraceptive Side-effects |
| 05_03 | Managing Side-effects and Complications of IUD and IUS |
| **e-SRH 06 and 07 Pregnancy** | |
| 06_01 | Planning Pregnancy |
| 07_01 | Unintended Pregnancy and Abortion |
| **e-SRH 10 Needs of specific groups** | |
| 10_01 | SRH Needs of Young People |
| 10_02 | SRH Needs of People Who Identify as LGBTQ or Non-binary |
| 10_04 | Contraceptive Needs of Women Following Pregnancy |
| 10_05 | Contraceptive Needs of Women with a Raised BMI |
| 10_06 | Contraceptive Needs of Women Aged Over 40 |
| **e-SRH 11 Adult and Child/Young Person (CYP) Safeguarding/Child Protection** | |
| 11_04_01 | Sexual Assault |
| **e-SRH 12 Psychosexual Medicine** | |
| 12_01 | Psychosexual Medicine |
| | |

# STIF Competency (Sexual Health Adviser)

| Sexual Health & HIV (HIV-STI) | |
|---|---|
| 1.01 | Sexual Behaviour and Infection Risk |
| 1.02 | Sexual History |
| 1.03 | Confidentiality in Sexual Health |
| 1.12 | Screening Asymptomatic Patients (may be numbered 11.xx) |
| 1.13 | Chlamydia Screening |
| 1.14 | Partner Notification, When and How? |
| 1.15 | Sexual Problems - Part 1 |
| 1.16 | Sexual Problems - Part 2 |
| 1.17 | Sexual Problems - Part 3 |
| 1.18 | Sexual Problems - Part 4 |
| 1.19 | Chemsex |
| 1.20 | Trans and Non-binary Sexual Health |
| | |
| 4.09 | Initial and Recurrent Episode HSV |
| 4.06 | Genital Herpes: Natural History and Complications |
| | |
| 8.01 | Consent, Competence and Confidentiality for Under 18s |
| 8.02 | Indicators of Child Sexual Abuse and Exploitation |
| 8.03 | Sexual Assault and Exploitation in Adults |
| 8.04 | Clinical Management of Sexual Assault in Adults and Young People |
| 8.05 | Child Sexual Abuse |
| 8.06 | Child Protection in Practice |
| 8.08 | STIs as a Marker of CSA and Assault |
| 8.10 | Psychological and Social Issues in Sexual Assault and Abuse |
| 8.12 | Sex Workers |
| | |
| 11.01 | HIV Testing |
| 11.02 | Antenatal HIV Testing |
| 11.03 | HIV Disclosure and Partner Notification |
| 11.05 | Sexual Exposure to HIV |
| 11.06 | Post Exposure Prophylaxis after sexual exposure (PEPSE) |
| 11.07 | HIV pre-exposure prophylaxis |
| | |
| e-SRH | http://www.e-lfh.org.uk/programmes/sexual-and-reproductive-healthcare/ |
| 01.05 | Working with Young People |
| | |
| Safeguarding Children (SGC) | http://www.e-lfh.org.uk/programmes/safeguarding-children |
| | Safeguarding Children - Level 1 |
| | Safeguarding Children - Level 2 |
| | Level 3 - Introduction: Attaining and Maintaining Safeguarding Competences |
| | |
| Female Genital Mutilation (FGM) | https://portal.e-lfh.org.uk/Component/Details/390922 |
| 01_02 | Communication skills for FGM Consultations |
| | |
| Child Sexual Exploitation (CSE) | https://www.e-lfh.org.uk/programmes/child-sexual-exploitation/ |
| | Combatting CSE |
| Domestic Violence and Abuse (DVA) | https://portal.e-lfh.org.uk/Component/Details/391662 |
| Mod 1 | Understanding domestic violence and abuse |
| Mod 2 | Identification of domestic violence and abuse |
| Mod 3 | Risk assessment for victims of domestic violence and abuse |

# STIF Advanced Competency

You should already have done some/most of the sessions above for STIF *Intermediate* Competency. We recommend that you revise the eLfH sessions done as part of the STIF *Intermediate* Competency module if more than 2 years have elapsed since you did them. If there are any in the list above which were not part of your original e-learning when you completed *Intermediate* Competency, you <u>must</u> complete them before starting your clinical topic-based assessments for the *Advanced* Competency pathway.

| HIV-STI 01 - Approach to Patient | |
|---|---|
| 1.15 | Sexual problems - Part 1 |
| 1.16 | Sexual problems - Part 2 |
| 1.17 | Sexual problems - Part 3 |
| 1.18 | Sexual problems - Part 4 |
| 1.19 | Chemsex |
| **HIV-STI 02 - Pathology** | |
| 2.06 | Diagnosing Syphilis |
| 2.13 | Diagnosing viral Hepatitis |
| **HIV-STI 03 - Bacterial STIs and related conditions** | |
| 3.07 | Epididymitis |
| 3.08 | Scrotal masses |
| 3.10 | Pelvic Inflammatory Disease: Overview |
| 3.11 | Acute pelvic pain and sepsis |
| 3.15 | Sexually acquired reactive arthritis |
| 3.17 | Urinary Tract Infections |
| 3.18 | Sexually transmitted enteric infections |
| **HIV-STI 04 - Genital Ulcer Disease** | |
| 4.02 | Early Infectious Syphilis |
| 4.03 | Positive Treponemal serology in an asymptomatic patient |
| 4.04 | Diagnosis and management of late Syphilis |
| 4.10 | Herpes in Pregnancy |
| **HIV-STI 05 - HPV infection, including HPV related neoplasia** | |
| 5.04 | Cervical Intraepithelial Neoplasia (CIN) |
| **HIV-STI 07 Viral Hepatitis** | |
| 7.01 | The Presentation of Infectious Hepatitis |
| **HIV-STI 08 - Sexual Assault / Abuse and Medicolegal issues** | |
| 8.06 | Child protection in practice |
| 8.10 | Psychological and social issues in relation to sexual assault and abuse |
| **HIV-STI 9a - Pregnancy and Children** | |
| 9a.01 | STIs in pregnancy |
| 9a.02 | Antenatal screening for Syphilis |

| HIV-STI 10 - Vaginal Discharge, vulvitis and balantis | |
|---|---|
| 10.05 | Recurrent BV, Candida and TV |
| 10.06 | Infective causes of balanitis |
| 10.07 | Infective causes of vulvitis |
| 10.08 | Genital dermatoses |

| HIV-STI 11 - HIV testing and prevention | |
|---|---|
| 11.02 | Antenatal HIV Testing |
| 11.07 | Pre Exposure Prophylaxis (PrEP)  - *NEW – access expected October 2020.* |

| HIV-STI 12 - Specific Assessment and Management of HIV | |
|---|---|
| 12.01 | Natural history of HIV infection |

| HIV-STI 17 – Gynaecology for GUM | |
|---|---|
| 17.01 | Normal and Abnormal Menstruation |
| 17.02 | Infertility |
| 17.03 | Bleeding Problems in Early Pregnancy |
| 17.05 | Benign and Malignant Tumours of the Ovary |
| 17.06 | Termination of Pregnancy (Therapeutic Abortion) |
| 17.07 | Endometrial Neoplasia |

| E-Derm | |
|---|---|
| 12.01 | Anatomy of the Mouth and Examination Technique |
| 12.19 | Recurrent Oral Ulceration |
| 12.20 | Oral Lichen Planus |
| 02.05 | Regional Variations of Psoriasis |
| 02.10 | Biological Drugs in Psoriasis |
| 03.03 | Exacerbating Factors in Atopic Eczema |
| 03.05 | Emollient Therapy in AD |
| 03.06 | Topical Steroids and Calcineurin Inhibitors |
| 04.01 | Seborrheic Dermatitis |
| 04.07 | Lichen Simplex |
| 04.11 | Lichen Planus |
| 06.03 | Systemic Lupus Erythematosus |
| 07.02 | Treatment of Vitiligo |
| 08.01 | Pemphigus |
| 11.09 | Severe Drug Eruptions |
| 20.08 | Lichen Planus – Female |
| 20.10 | Lichen Sclerosus – Female |
| 20.13 | VIN, PIN and VAIN |
| 20.20 | Non STI – Male |
| 20.21 | Non STI – Female |
| 20.23 | Bullous Disorders of the Genitalia |
| 20.45 | LGV, Chancroid and Donovanosis |
| 20.39 | Infective Causes of Balanitis |
| 20.40 | Infective Causes of Vulvitis |
| 20.24 | Non-infective Genital Ulceration |
| 20.28 | Genital Oedema |
| 20.33 | Localised Vulval Pain |
| 21.02 | Staphylococcal Related Skin Disorders |
| 22.03 | Diffuse Pigmented Naevi |
| 22.07 | Actinic Keratosis and Bowen's Disease |

| | |
|---|---|
| 22.13 | Cysts |
| 26.03 | Introduction to Psychosocial Management in Dermatology |
| 28.02 | Topical Corticosteroids and Appropriate Use in Dermatology I |
| 28.03 | Topical Corticosteroids and Appropriate Use in Dermatology II |
| 28.08 | Topical Antifungal Agents |

| Domestic Violence and Abuse (DVA) https://portal.e-lfh.org.uk/Component/Details/391662 | |
|---|---|
| Module 1 | Understanding domestic violence and abuse |
| Module 2 | Identification of domestic violence and abuse |
| Module 3 | Risk assessment for victims of domestic violence and abuse |

| Three free e-learning resources from the Royal College of General Practitioners | |
|---|---|
| RCGP 1 | Endometreosis https://elearning.rcgp.org.uk/course/info.php?id=307 |
| RCGP 2 | Heavy Menstrual Bleeding https://elearning.rcgp.org.uk/course/info.php?id=351 |
| RCGP 3 | Bloating and other Abdominal Symptoms: Could it be Ovarian Cancer? https://elearning.rcgp.org.uk/course/info.php?id=121 |

# NHIVNA-STIF Intermediate Competency

There are two sets of e-learning to be completed as part of the STIF *NHIVNA Intermediate* Competency training and assessment programme, **NHIVNA HIV E-Learning and e-learning for healthcare (eHIV-STI)**

## 1. NHIVNA HIV E-Learning
http://www.nhivna.org/NHIVNA-HIV-nursing-modules.aspx

The NHIVNA HIV Nursing Modules aim to support nurses who are working toward Levels 2 and 3 of the National HIV Nursing Competencies. Participation in the NHIVNA HIV Nursing Modules is free of charge and access is open to all. If you do not already have a NHIVNA website account, please register https://www.nhivna.org/NewRegistration

There is a time limit of 1 hour to work through each tutorial. To show learning and enhance your portfolio, please choose one of the Case Studies at the end of each tutorial.  There is also a form for you to provide feedback at the end, which must be completed within this time. Once you have completed the feedback form, you will be issued with a certificate of participation. Please keep an electronic copy of this and upload all of these (ideally as a single merged document) to your 'personal library' in the e-portfolio

| Module 1 – Understanding HIV | |
| --- | --- |
| 1A What is HIV? | When you have completed this tutorial, you will be able to: <br><br> Demonstrate an understanding of different routes of transmission of HIV <br><br> Demonstrate knowledge of the virus and its mechanism of action <br><br> Describe how the virus establishes itself within the body <br><br> Explain the effects of the virus on the immune system and its repercussions <br><br> Explain the value of measuring CD4 and viral load levels <br><br> Describe the course of HIV infection and stages of disease |
| 1B Opportunistic Infections | When you have completed this tutorial, you will be able to: <br><br> Identify common opportunistic infections and their active/prophylactic management <br><br> Understand the impact of immunosuppression on developing cancers and the types of cancer that are most common amongst people living with HIV |
| 1C HIV testing and diagnosis | When you have completed this tutorial, you will be able to: <br><br> Explain how HIV policy has shifted to focus on early detection and effective management of HIV as a chronic condition <br><br> Demonstrate knowledge of commonly used diagnostic tests and the rationale behind them <br><br> Describe the transmission dynamics of HIV and identify the resources available to reduce transmissible risk <br><br> Develop an insight into the emotional needs of the patient at challenging times like receiving a positive diagnosis <br><br> Demonstrate an awareness of issues around the disclosure of HIV status including emergency prophylactic treatment for those that discover a sexual and/or needle sharing partner has HIV and the legal implications of non-disclosure |

| **Module 2 - Caring for people with HIV** | |
|---|---|
| 2A. Assessing health and well-being | When you have completed this tutorial, you will be able to: <br><br> Demonstrate an understanding of the assessment needs of patients, from both a physical and psychosocial perspective <br><br> Understand the role of the nurse in the assessment of physical wellbeing and social care needs, including the accurate recording of information and the communication of findings in a timely way to relevant Health Care Professionals <br><br> Identify the different information needs of individuals <br><br> Discuss and explain treatment options relevant to the patient's level of understanding <br><br> Develop an insight into the possible psychological, emotional and spiritual needs of patients depending on the stage of disease development and their socio-economic and socio-cultural backgrounds <br><br> Help people living with HIV identify the support they need through positive nurse-patient interaction |
| 2B. Supporting psychological and social care needs | When you have completed this tutorial, you will be able to: <br><br> Understand the factors that can affect living positively with HIV <br><br> Identify key nursing interventions that can support and encourage positive living <br><br> Help to facilitate skills development that can enable people to manage their condition effectively <br><br> Encourage people to develop strategies that can help them to cope with their condition long-term <br><br> Find out about local services and social care agencies that may help people to develop themselves personally <br><br> Understand the importance of the support available within your multi-disciplinary team and know how, and to whom, people in your care should be referred to |
| **Module 3 - Antiretroviral therapy** | |
| 3A. ART | When you have completed this tutorial, you will be able to: <br><br> Explain the role of antiretroviral therapy and the rationale for when ART should be initiated <br><br> Describe the principles of combination therapy - its goals, commonly used combinations and relevant policies and protocols <br><br> Demonstrate an understanding of the different classes of ART drugs - their mode of action, administration and main side effects <br><br> Explain the impact of resistance, reduced adherence and drug-drug interactions on therapy and changing treatment <br><br> Describe how ongoing drug development has the potential to improve future ART, and understand the rationale for keeping up to date with related pharmacological developments and relevant research findings |
| 3B ART and patient wellbeing | When you have completed this tutorial, you will be able to: <br><br> Identify actual or potential problems with therapy and adherence <br><br> Signpost patients experiencing problems with therapy to the right person <br><br> Support patients in coping with short and long-term side effects of treatment <br><br> Recognise the potential psychological impact of side effects <br><br> Develop an insight into the emotional needs of the patient during challenging times such as starting or switching therapy |

| Module 4 - Health promotion | |
|---|---|
| 4A. Importance of a healthy lifestyle | When you have completed this tutorial, you will be able to: <br><br> Describe the importance of promoting a healthy lifestyle to those in your care <br> Access local and national sources of support for your patients, relating to Exercise, Smoking, Alcohol and Recreational drugs <br> Understand your local referral process for cardiovascular and metabolic diseases <br> Be aware of guidelines for immunisation in HIV <br> Explain the considerations around travelling with HIV and the implications for maintaining treatment whilst away from home |
| **Module 4 - Health promotion** <br> 4B. Supporting sexual and reproductive health | When you have completed this tutorial, you will be able to: <br> Develop an insight into the sexual health needs of people living with HIV and how best to support them <br> Access guidelines for the management of HIV in relation to the sexual health needs of people living with HIV and understand their right to sexual fulfilment <br> Develop an understanding about managing STIs in people living with HIV and access guidelines for the same <br> Understand the reproductive needs of people living with HIV and their right to reproductive fulfilment <br> Describe strategies to prevent the transmission risk presented from conception right through to after delivery |
| **Module 5 - HIV testing** | |
| 5A. HIV testing: background and key principles | When you have completed this tutorial, you will be able to: <br> Understand the importance of HIV testing <br> Know to whom (and when) an HIV test should be offered <br> Recognise the different types of HIV tests and when to use them <br> Understand how to interpret test results |
| 5B. Risk assessment, pre and post-test discussion | When you have completed this tutorial, you will be able to: <br> Understand the risks involved for each route of transmission <br> Understand the key elements of pre-test discussion, particularly the need to gain informed consent <br> Understand the key elements of post-test discussion, depending on the result <br> Demonstrate an awareness of HIV-testing issues that may be relevant to different population groups |
| **Module 5 - HIV testing** <br> 5C. Fundamentals of Point of Care Testing (POCT) | When you have completed this tutorial, you will be able to: <br> Understand the rationale for point of care testing <br> Be aware of the different types of home tests available <br> Appreciate the key clinical and information governance systems required when establishing an HIV testing service |
| **Module 9 – PrEP** | |

| 9A Pre-exposure Prophylaxis | This module covers: |
|---|---|
| | What PrEP is and who it is for |
| | The evidence base for PrEP including adherence, starting stopping and re starting PrEP and the indication for PEP |
| | The HIV Virus (lifecycle) |
| | PREP Dosing |
| | The Consultation Side effects & management Missed PILLS |
| | the major points, investigations, considerations which should be actioned before PREP should be started PrEP & other HIV prevention strategies |
| | PrEP & partners |
| | Pros & Cons of using PrEP |
| | Additional Health screening & Prevention when using PREP |

## 2. E-learning for Healthcare (e-LfH) for STIF-NHIVNA *Intermediate*

| Sexual Health & HIV (HIV-STI) | |
|---|---|
| **Approach to Patient** | |
| 01_01 | Sexual Behaviour and Infection Risk |
| 01_02 | Sexual History |
| 01_03 | Confidentiality in Sexual Health |
| 01_12 | Screening Asymptomatic Patients |
| 01_14 | Partner Notification When and How |
| 01_19 | Chemsex |
| 01_20 | Sexual / Reproductive Healthcare for Trans, Non-binary and Intersex People |
| **Sexual Assault/Abuse and Medicolegal issues** | |
| 08_03 | Sexual assault and exploitation in adults |
| **HIV (Special Circumstances)** | |
| 09b_15 | HIV in MSM |
| **HIV Testing and Prophylaxis** | |
| 11_03 | HIV disclosure and Partner Notification |
| 11_05 | Sexual exposure to HIV |
| **System-specific HIV associated conditions** | |
| 14_10 | Nutrition in HIV care (incl. HIV wasting syndrome) |
| | |
| **Domestic Violence and Abuse (DVA)** https://portal.e-lfh.org.uk/Component/Details/391662 | |
| | Understanding domestic violence and abuse |
| | Identification of domestic violence and abuse |
| | Risk assessment for victims of domestic violence and abuse |
| | |

# NHIVNA-STIF Advanced Competency

There are two sets of e-learning to be completed as part of the STIF *NHIVNA Advanced* Competency training and assessment programme.
- **NHIVNA HIV E-Learning**
- **E-learning for Healthcare (NHS England)**

It is recommended that you complete at least 50% of the e-learning before undertaking the clinical assessments.
You should ask for some protected time to undertake this e-learning if you are to get the most benefit.
We do acknowledge that the eLfH modules were designed for use in the training of doctors but we still feel that they are relevant and useful for nurse training as well.

### 1. NIVNA HIV E-Learning
http://www.nhivna.org/NHIVNA-HIV-nursing-modules.aspx

The NHIVNA HIV Nursing Modules aim to support nurses who are working toward Levels 2 and 3 of the National HIV Nursing Competencies. Participation in the NHIVNA HIV Nursing Modules is free of charge and access is open to all. If you do not already have a NHIVNA website account, please register
https://www.nhivna.org/NewRegistration

There is a time limit of 1 hour to work through each tutorial. To show learning and enhance your portfolio, please choose one of the Case Studies at the end of each tutorial.  There is also a form for you to provide feedback at the end, which must be completed within this time. Once you have completed the feedback form, you will be issued with a certificate of participation. Please keep an electronic copy of this and upload all of these (ideally as a single merged document) to your 'personal library' in the e-portfolio

| Module 6 - Managing complexity in Antiretroviral Therapy management | |
|---|---|
| *A - Drug resistance* | When you have completed this tutorial, you will be able to:<br>• Understand what drug resistance is and how it develops in HIV<br>• Describe the different types of drug resistance in terms of development, prevalence and how they differ from one another<br>• Understand the consequences of drug resistance and how it impacts the treatment of HIV<br>• Understand the mechanisms behind the development of drug resistance in respect to different classes of drugs<br>• Explain drug resistance to your patients in a simple, informative way |
| *B - The genetics behind HIV and clinical investigations* | When you have completed this tutorial, you will be able to:<br>• Describe how polymorphisms and mutations occur, and how they related to resistance of HIV<br>• Describe the different techniques of drug resistance testing and how they can help tailor drug therapy<br>• Understand how resistance testing can help develop novel drug treatments for targeted therapy for those with HIV drug resistance<br>• Identify patients who may benefit from drug resistance testing<br>• Understand the advantages and limitations of drug resistance testing<br>• Describe tropism, its testing and identify which patients are recommended to undergo tropism testing<br>• Identify the pros and cons of TDM and when it should be adopted |
| *C – Drug-Drug interactions* | When you have completed this tutorial, you will be able to:<br>• Describe the differences and effects of pharmacodynamic and pharmacokinetic drug interactions<br>• Identify potential drug-drug interactions<br>• Describe the part NTRIs, NNRTIs and PIs play in drug-drug interactions<br>• Understand your role in preventing the onset of potential drug-drug interactions |
| *6D. Adherence and drug resistance* | When you have completed this tutorial, you will be able to:<br>• Understand the key steps required to maximise adherence in patients receiving ART<br>• Understand the key principles of motivational interviewing and how it can be successfully implemented in HIV patients to help improve adherence<br>• With further training, adopt motivational interviewing as part of your ongoing interventions with your patients |

| | |
|---|---|
| *6E - Discontinuation* | When you have completed this tutorial, you will be able to:<br>• Understand the reasons for discontinuation of treatment<br>• Chose the most appropriate strategy for managing the discontinuation of treatment based on an individual patient basis and the latest available evidence<br>• Identify and explain to patients the risks associated with discontinuation of treatment and the dangers of viral rebound<br>• Describe the effect of drug discontinuation on CD4 cell counts and its related consequences |
| *6F. Supporting and informing patients* | When you have completed this tutorial, you will be able to:<br><br>• Provide the best advice for your patients surrounding their treatment<br>• Address any concerns your patients may have regarding their treatment, drug resistance and the associated potential risks<br>• Explain what is meant by 'forgiveness' when talking about certain ART medicines, to your patients<br>• Explain what 'blips' are and how they arise and how they can be used to indicate how well a treatment is working |
| **Module 8 – HIV and Ageing** | |
| *8A - Defining Ageing with and without HIV* | When you have completed this tutorial, you will be able to:<br>• Identify key challenges relating to HIV and ageing, including the impact of an ageing population<br>• Explore these challenges in relation to different HIV-positive cohorts<br>• Examine what can be learnt from the care and management of people with other long-term conditions<br>• Identify your own skills and support requirements in addressing issues relating to HIV and Ageing and how to discuss these issues with your client group |
| *8B - Implications of HIV and Ageing* | Growing older with HIV will bring many challenges: There are many complexities to treating and caring for those patients ageing with HIV. Not just the uncertainty of the effects of long-term ART and HIV infection, but also issues around polypharmacy and many of the issues listed below:<br>**1. Immune system**<br>**2. Co-morbidities**<br>**3. Mental health**<br>**4. Social care**<br>**5. Work and finance** |
| *8C - Working with HIV and Ageing* | With an ageing HIV population, thoughts around supported care leave many anxious. As HIV moves into mainstream care many staff may have outdated views about HIV and AIDS, and for those living with HIV, stigma and discrimination remain a real problem, not only around HIV but regarding their sexuality. The ageing HIV population will put new challenges and demands upon primary and secondary care services and care management will need to integrate with other disciplines such as geriatric medicine, oncology and cardiology. |

# E-learning for Healthcare (e-LfH)

## e-HIV STI to be completed for STIF *NHIVNA Advanced* Competency

| | |
|---|---|
| **Sexual Health & HIV (HIV-STI)** | |
| **Viral Hepatitis** | |
| 07_07 | Hepatitis B & C and HIV co-infection |
| **HIV (Special Circumstances)** | |
| 09b_09 | HIV in women |
| 09b_10 | HIV and reproductive health and fertility |
| 09b_11 | HIV in Pregnancy |
| 09b_12 | ARVs in pregnancy |
| 09b_13 | Adolescent HIV |
| **HIV Testing and Prophylaxis** | |
| 11_02 | Antenatal HIV testing |
| 11_04 | Occupational exposure to HIV |
| 11_06 | PEPSE |
| **Specific assessment and management of HIV** | |
| 12_01 | Natural History of HIV infection |
| 12_02 | Baseline assessment of HIV-positive individuals and routine monitoring |
| 12_05 | First line ARV |
| 12_07 | ARV side-effects and toxicities |
| 12_09 | ARV treatment failure |
| 12_10 | ARV resistance testing |
| 12_11 | ARV drug interactions and therapeutic drug monitoring (TDM) |
| **Assessment and management of opportunistic HIV infections** | |
| 13_01 | Pneumococcal infections in HIV |
| 13_04 | Tuberculosis |
| 13_08 | Herpes infections |
| 13_11 | CMV |
| 13_12 | Cryptosporidiosis and Microsporidiosis |
| **System-specific HIV-associated conditions** | |
| 14_01 | Haematology and HIV |
| 14_02 | Neurology and HIV |
| 14_03 | Endocrine/metabolic disorders and HIV |
| 14_04 | Respiratory Disease and HIV |
| 14_05 | Cardiac Disease and HIV |
| 14_06 | Gastrointestinal disease and HIV |
| 14_07 | Renal disease and HIV |
| 14_08 | Skin disease and HIV |
| **HIV associated malignancies** | |
| 15_01 | HIV related malignancy |
| | |